These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 31301097

  • 1. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
    Li X, Zhou J, Chu C, You Q, Zhong R, Rao Z, Hu W.
    Head Neck; 2019 Oct; 41(10):3525-3534. PubMed ID: 31301097
    [Abstract] [Full Text] [Related]

  • 2. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW.
    Ann Oncol; 2018 Sep 01; 29(9):1972-1979. PubMed ID: 30016391
    [Abstract] [Full Text] [Related]

  • 3. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
    Fang FM, Huang TL, Lin YH, Chien CY, Chuang HC, Luo SD, Lin HC, Lin YT, Li SH, Liao KC, Tsai WL.
    Head Neck; 2019 May 01; 41(5):1282-1289. PubMed ID: 30548091
    [Abstract] [Full Text] [Related]

  • 4. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L, Wu Z, Xie D, Lv S, Xia L, Su Y.
    Radiat Oncol; 2020 Jul 02; 15(1):160. PubMed ID: 32615984
    [Abstract] [Full Text] [Related]

  • 5. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
    Zang J, Li C, Xu M, Xu W, Kang X, Wang J, Luo S, Shi M.
    Sci Rep; 2018 Sep 06; 8(1):13318. PubMed ID: 30190563
    [Abstract] [Full Text] [Related]

  • 6. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
    Topkan E, Yucel Ekici N, Ozdemir Y, Besen AA, Mertsoylu H, Sezer A, Selek U.
    Ear Nose Throat J; 2021 Feb 06; 100(2):NP69-NP76. PubMed ID: 31184210
    [Abstract] [Full Text] [Related]

  • 7. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q, Xu G, Xia Y, Zuo J, Zeng G, Xue Z, Cao R, Xiong W, Li W.
    Oral Oncol; 2020 Dec 06; 111():104925. PubMed ID: 32721816
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
    Liu LT, Chen QY, Tang LQ, Guo SS, Guo L, Mo HY, Li Y, Tang QN, Sun XS, Liang YJ, Zhao C, Guo X, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ.
    J Natl Compr Canc Netw; 2019 Jun 01; 17(6):703-710. PubMed ID: 31200353
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C, Tang X, Wang J, Song J, Xu Y.
    Otolaryngol Head Neck Surg; 2017 Aug 01; 157(2):233-238. PubMed ID: 28418781
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis.
    Lan M, Chen C, Huang Y, Tian L, Duan Z, Han F, Liao J, Deng M, Sio TT, Prayongrat A, Zheng L, Wu S, Lu T.
    Sci Rep; 2017 Feb 17; 7():42624. PubMed ID: 28211482
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J, Thephamongkhol K.
    BMC Cancer; 2018 Mar 27; 18(1):329. PubMed ID: 29587665
    [Abstract] [Full Text] [Related]

  • 14. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
    Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Wen YF, Guo L, Mo HY, Chen MY, Sun Y, Ma J, Tang LQ, Mai HQ.
    Eur J Cancer; 2019 Mar 27; 110():24-31. PubMed ID: 30739837
    [Abstract] [Full Text] [Related]

  • 15. Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy.
    Zhang C, Wang SF, Zhang YL, Teng CX.
    BMC Cancer; 2024 Aug 15; 24(1):1012. PubMed ID: 39148032
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH.
    Eur J Cancer; 2017 Apr 15; 75():14-23. PubMed ID: 28214653
    [Abstract] [Full Text] [Related]

  • 17. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY.
    Eur J Cancer; 2019 Sep 15; 119():87-96. PubMed ID: 31425966
    [Abstract] [Full Text] [Related]

  • 18. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C, Sun R, Tang LL, Chen L, Li WF, Mao YP, Zhou GQ, Guo R, Lin AH, Sun Y, Ma J, Hu WH.
    Oral Oncol; 2018 Mar 15; 78():37-45. PubMed ID: 29496056
    [Abstract] [Full Text] [Related]

  • 19. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
    Chen TM, Lin KC, Yuan KS, Chang CL, Chow JM, Wu SY.
    Radiother Oncol; 2018 Oct 15; 129(1):23-29. PubMed ID: 29277447
    [Abstract] [Full Text] [Related]

  • 20. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, Li CF, Zou X, Yu T, Cao JY, Zhang MX, Jiang R, Sun R, Mo HY, Guo L, Cao KJ, Lin AH, Sun Y, Qian CN, Ma J, Chen MY.
    Theranostics; 2017 Oct 15; 7(8):2314-2324. PubMed ID: 28740554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.